Associated Banc Corp Acquires 3,094 Shares of Eli Lilly and Company (NYSE:LLY)

Associated Banc Corp boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 6.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 54,497 shares of the company’s stock after acquiring an additional 3,094 shares during the period. Eli Lilly and Company accounts for 1.4% of Associated Banc Corp’s holdings, making the stock its 16th biggest position. Associated Banc Corp’s holdings in Eli Lilly and Company were worth $45,010,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC lifted its holdings in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department increased its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the 1st quarter worth $40,000. Mascagni Wealth Management Inc. bought a new position in Eli Lilly and Company during the 4th quarter worth $43,000. Finally, O Brien Wealth Partners LLC increased its stake in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after acquiring an additional 12 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on LLY shares. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,012.56.

Eli Lilly and Company Stock Up 0.7%

NYSE LLY opened at $767.75 on Tuesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a market capitalization of $727.63 billion, a PE ratio of 62.47, a PEG ratio of 1.08 and a beta of 0.44. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The business’s 50-day moving average is $776.59 and its 200 day moving average is $800.81.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.